An innovative method to optimize cosmeceutical delivery to skin Natural, safe, painless, sustainable transdermal microinjection based on sea anemone nematocysts
Optimal transdermal delivery of cosmeceuticals is considered to be the “holy grail” of effective skin care. Because skin is a challenging barrier, meeting consumer expectations of anti-aging products remains elusive. Monterey Bay Labs has achieved a notable breakthrough in transdermal delivery by isolating microinjectors used by the starlet sea anemone (Nematostella vectensis) to anesthetize prey. These microinjectors comprise a sophisticated system of microcapsular nematocysts that facilitate penetration of submicron tubules to deliver their contents, repurposed into a topical formulation that painlessly, immediately penetrates skin, actively delivering cosmeceutical formulations into the epidermis. Previous research has repeatedly validated its advantages. The present paper describes a randomized, intra-individual, single-blind study in 21 healthy women (aged ≥36). Investigational InoCyte™ was applied to one side of the face, and placebo to the other, for 30 days. InoCyte was associated with a 23.0% improvement from baseline in wrinkle condition and hydration level at the eye area (p<0.05), without significant change with placebo. With InoCyte, there were no adverse effects, and overall subject satisfaction was high (90%).
InoCyte is uniquely advantageous and safe for treating skin wrinkles.
Revenue of the U.S. cosmetic industry is estimated to amount to approximately USD 62.46 billion in 2016 (1) and the global beauty market is expected to reach USD 265 billion by the year 2017. Skin care is the largest segment, represented largely by anti-aging and anti-wrinkle products, which are predicted to drive market growth (2).
Manufacturers of skin care products are quick to promise anti-aging and similar effects in response to consumer interest, but thus far have come up short on results. The advent of consumer panels and social media has elevated the pressure on companies to improve performance or risk losing revenue. It is increasingly acknowledged that optimal transdermal delivery of